NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00814073,Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis,https://clinicaltrials.gov/study/NCT00814073,AB06006,COMPLETED,The objective of this study is to compare the safety and efficacy of masitinib (AB1010) to placebo in patients with mastocytosis with handicap.,NO,Indolent Systemic Mastocytosis,DRUG: Masitinib|DRUG: Placebo|OTHER: Best Supportive Care,"Cumulative response (4R75%), The prospectively declared primary endpoint (4R75%) was cumulative response in at least one of four severe baseline symptoms of mast cell mediator release (pruritus, flushes, depression, or asthenia). Response was defined as a 75% improvement from baseline for any of these four symptoms. Cumulative response was defined as the number of actual responses between weeks 8 and 24, divided by the total number of possible responses over the same treatment period (ie, with five scheduled visits, each patient had a maximum of five to 20 possible responses depending on the number of severe baseline symptoms)., 24 weeks","Cumulative response (3R75%), Cumulative response in at least one of three severe baseline symptoms (pruritus, flushes, or depression), 24 weeks|Cumulative response (2R75%), Cumulative response in at least one of three severe baseline symptoms (pruritus or flushes), 24 weeks",,AB Science,,ALL,"ADULT, OLDER_ADULT",PHASE3,135,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT",AB06006,2008-12,2015-11,2015-11,2008-12-23,,2019-12-03,"UC Davis Health System , Department of Dermatology, Sacramento, California, 95816, United States|MD Anderson Cancer Centre, Houston, Texas, 77030, United States|CHU d'Amiens, Amiens, France|Hôpital Avicenne, Bobigny, France|CHU de Brest, Brest, France|CHU de Caen, Caen, France|CHU Clermont Ferrand, Clermont Ferrand, 63000, France|Hôpital Claude Huriez, Lille, France|CHU Dupuytren, Limoges, France|Hôpital Ambroise Paré, Marseille, France|Hôpital Nord, Marseille, France|Hôpital Central, Nancy, France|CHU Hôtel Dieu, Nantes, France|Hôpital l'Archet II, Nice, France|Hôpital Necker, Paris, France|Hôpital Tenon, Paris, France|CHU Lyon Sud, Pierre Bénite, 69495, France|Centre Hospitalier Lyon Sud, Pierre-Bénite, France|CHU Milétrie, Poitiers, France|CHU Hôpital Sud, Rennes, France|CHU de Saint-Etienne, Saint-Etienne, France|Hôpital Purpan, Toulouse, France|Hôpital Bretonneau, Tours, France|Hôpital des Hauts Clos, Troyes, France",
